<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ETHINYLESTRADIOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ETHINYLESTRADIOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of symptoms of oestrogen deficiency</span>,
                <span class="indication">Osteoporosis prophylaxis if other drugs cannot be used</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Female hypogonadism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Menstrual disorders</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Palliative treatment of prostate cancer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction)</li>
            <li>active thrombophlebitis</li>
            <li>Dubin-Johnson and Rotor syndromes (or monitor closely)</li>
            <li>gallstones</li>
            <li>heart disease associated with pulmonary hypertension</li>
            <li>heart disease associated with risk of embolus</li>
            <li>history during pregnancy of cholestatic jaundice</li>
            <li>history during pregnancy of chorea</li>
            <li>history during pregnancy of pemphigoid gestationis</li>
            <li>history during pregnancy of pruritus</li>
            <li>history of breast cancer</li>
            <li>history of haemolytic uraemic syndrome</li>
            <li>liver disease (where liver function tests have failed to return to normal)</li>
            <li>migraine with aura</li>
            <li>oestrogen-dependent cancer</li>
            <li>sclerosing treatment for varicose veins</li>
            <li>severe or multiple risk factors for arterial disease</li>
            <li>severe or multiple risk factors for venous thromboembolism</li>
            <li>systemic lupus erythematosus with (or unknown) antiphospholipid antibodies</li>
            <li>thrombophilic disorder</li>
            <li>transient cerebral ischaemic attacks without headaches</li>
            <li>undiagnosed vaginal bleeding</li>
            <li>untreated endometrial hyperplasia</li>
            <li>venous thromboembolism, or history of recurrent venous thromboembolism (unless already on anticoagulant treatment)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Gallstones, systemic lupus erythematosus,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal bloating, abdominal cramps, absence of withdrawal bleeding, altered blood lipids (may lead to pancreatitis), amenorrhoea after discontinuation, breast enlargement, breast secretion, breast tenderness, cervical erosion, changes in libido, changes in lipid metabolism, changes in vaginal discharge, chloasma, cholestatic jaundice, chorea, contact lenses may irritate, depression, dizziness, feminising effects, fluid retention, glucose intolerance, headache, hepatic tumours, hypertension, irritability, leg cramps (rule out venous thrombosis), liver impairment, migraine, mood changes, nausea, nervousness, photosensitivity, premenstrual-like syndrome, rashes, reduced menstrual loss, skin reactions, sodium retention, symptoms of endometriosis may be exacerbated, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB), uterine fibroids may increase in size, vaginal candidiasis, visual disturbances, vomiting, weight changes, &#8216;spotting&#8217; in early cycles,
              </p>
        
        
            <section class="advice">
                <h3>Withdrawal bleeding</h3>
              <p>Cyclical HRT (where a progestogen is taken for 12&#8211;14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
            cardiovascular disease (sodium retention with oedema, thromboembolism)
          </li>
          <li>
            Crohn&#8217;s disease
          </li>
          <li>
            diabetes (increased risk of heart disease)
          </li>
          <li>
            gene mutations associated with breast cancer (e.g. BRCA&#8239;1)
          </li>
          <li>
            history of breast nodules or fibrocystic disease&#8212;closely monitor breast status (risk of breast cancer)
          </li>
          <li>
            history of endometrial hyperplasia
          </li>
          <li>
            history of severe depression (especially if induced by hormonal contraceptive)
          </li>
          <li>
            hyperprolactinaemia (seek specialist advice)
          </li>
          <li>
            hypophyseal tumours
          </li>
          <li>
            increased risk of gall-bladder disease
          </li>
          <li>
            inflammatory bowel disease
          </li>
          <li>
            migraine (migraine-like headaches)
          </li>
          <li>
            personal or family history of hypertriglyceridaemia (increased risk of pancreatitis)
          </li>
          <li>
            presence of antiphospholipid antibodies (increased risk of thrombotic events)
          </li>
          <li>
            prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer
          </li>
          <li>
            risk factors for arterial disease
          </li>
          <li>
            risk factors for migraine
          </li>
          <li>
            risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative)
          </li>
          <li>
            risk factors for venous thromboembolism
          </li>
          <li>
            sickle-cell disease
          </li>
          <li>
            undiagnosed breast mass
          </li>
        </ul>
        <ul>
          <li>
            <p>The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present, see above). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.</p>
          </li>
          <li>
            <p>Use with <b>caution</b> if any of following factors present but <b>avoid</b> if two or more factors present:</p><ul>
        <li>
        <i>family history of venous thromboembolism</i> in first-degree relative aged under 45 years (avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));</li>
        <li>
        <i>obesity</i>&#8212;body mass index &#8805;30&#8239;kg/m<sup>2</sup> (avoid if body mass index &#8805;35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li>
        <li>
        <i>long-term immobilisation</i> e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);</li>
        <li>
        <i>history of superficial thrombophlebitis;</i>
        </li>
        <li>
        <i>age</i> over 35 years (avoid if over 50 years);</li>
        <li>
        <i>smoking.</i>
        </li>
        </ul>
          </li>
          <li>
            <p>Use with <b>caution</b> if any one of following factors present but <b>avoid</b> if two or more factors present:</p><ul>
        <li>
        <i>family history of arterial disease</i> in first degree relative aged under 45 years (avoid if atherogenic lipid profile);</li>
        <li>
        <i>diabetes mellitus</i> (avoid if diabetes complications present);</li>
        <li>
        <i>hypertension</i>&#8212;blood pressure above <i>systolic 140&#8239;mmHg</i> or <i>diastolic 90&#8239;mmHg</i> (avoid if blood pressure above <i>systolic 160&#8239;mmHg</i> or <i>diastolic 95&#8239;mmHg</i>); (In adolescents, avoid if blood pressure very high);</li>
        <li>
        <i>smoking</i> (avoid if smoking 40 or more cigarettes daily);</li>
        <li>
        <i>age</i> over 35 years (avoid if over 50 years);</li>
        <li>
        <i>obesity</i> (avoid if body mass index &#8805;35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li>
        <li>
        <i>migraine without aura</i> (avoid if <i>migraine with aura</i> (focal symptoms), <i>or</i> severe migraine frequently lasting over 72 hours despite treatment, <i>or</i> migraine treated with ergot derivatives).</li>
        </ul>
          </li>
          <li>
            <p>Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ETHINYLESTRADIOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            tablet,
            oral suspension,
            capsule,

            <div id="PHP75511"><a href="../medicinalForm/PHP75511.html" data-target="#PHP75511" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
